To evaluate the safety and efficacy of INCB018424 PHOSPHATE CREAM in cutaneous LP as assessed
by the change in Physician Global Assessment (PGA), Body Surface Area (BSA), Index Treatment
and Control Lesion by Clinical Assessment Scale of Severity for Index Lesion Signs and
Symptoms (CAILS) score, Pruritus Numerical Rating Scale (NRS), and Skindex-16. To predict
responses through the identification of unique biomarkers of LP at week 0 and utilizing RNA
sequencing on responsive and non-responsive tissue at week 4.